JP2018516983A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018516983A5 JP2018516983A5 JP2018513744A JP2018513744A JP2018516983A5 JP 2018516983 A5 JP2018516983 A5 JP 2018516983A5 JP 2018513744 A JP2018513744 A JP 2018513744A JP 2018513744 A JP2018513744 A JP 2018513744A JP 2018516983 A5 JP2018516983 A5 JP 2018516983A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- nucleic acid
- item
- hsv
- guide rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020004707 nucleic acids Proteins 0.000 claims description 40
- 102000039446 nucleic acids Human genes 0.000 claims description 40
- 150000007523 nucleic acids Chemical class 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 35
- 241000700584 Simplexvirus Species 0.000 claims description 32
- 108091033409 CRISPR Proteins 0.000 claims description 21
- 108020005004 Guide RNA Proteins 0.000 claims description 19
- 239000013598 vector Substances 0.000 claims description 14
- 230000000295 complement effect Effects 0.000 claims description 12
- 239000002105 nanoparticle Substances 0.000 claims description 9
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 102000004389 Ribonucleoproteins Human genes 0.000 claims description 6
- 108010081734 Ribonucleoproteins Proteins 0.000 claims description 6
- 241000700605 Viruses Species 0.000 claims description 6
- 229920006317 cationic polymer Polymers 0.000 claims description 6
- 239000002502 liposome Substances 0.000 claims description 6
- 239000002082 metal nanoparticle Substances 0.000 claims description 6
- 239000002073 nanorod Substances 0.000 claims description 6
- 229940037201 oris Drugs 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 241000710929 Alphavirus Species 0.000 claims description 5
- 241000702421 Dependoparvovirus Species 0.000 claims description 5
- 241000713666 Lentivirus Species 0.000 claims description 5
- 241000700618 Vaccinia virus Species 0.000 claims description 5
- 239000013612 plasmid Substances 0.000 claims description 5
- 241000701161 unidentified adenovirus Species 0.000 claims description 5
- 241001529453 unidentified herpesvirus Species 0.000 claims description 5
- 241001430294 unidentified retrovirus Species 0.000 claims description 5
- -1 cationic lipid Chemical class 0.000 claims description 4
- 229940100613 topical solution Drugs 0.000 claims description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 3
- 230000010076 replication Effects 0.000 claims description 3
- 125000002091 cationic group Chemical group 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 208000009889 Herpes Simplex Diseases 0.000 claims 3
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 1
- 101710163270 Nuclease Proteins 0.000 description 45
- 241000701022 Cytomegalovirus Species 0.000 description 31
- 230000008685 targeting Effects 0.000 description 15
- 208000015181 infectious disease Diseases 0.000 description 6
- 238000010459 TALEN Methods 0.000 description 5
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 5
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 238000010354 CRISPR gene editing Methods 0.000 description 3
- 230000005782 double-strand break Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 238000001216 nucleic acid method Methods 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 230000005889 cellular cytotoxicity Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000009295 sperm incapacitation Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562168262P | 2015-05-29 | 2015-05-29 | |
| US201562168259P | 2015-05-29 | 2015-05-29 | |
| US62/168,259 | 2015-05-29 | ||
| US62/168,262 | 2015-05-29 | ||
| PCT/US2016/034606 WO2016196273A1 (en) | 2015-05-29 | 2016-05-27 | Compositions and methods to treat viral infections |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018516983A JP2018516983A (ja) | 2018-06-28 |
| JP2018516983A5 true JP2018516983A5 (OSRAM) | 2019-06-27 |
Family
ID=57441664
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018513744A Pending JP2018516983A (ja) | 2015-05-29 | 2016-05-27 | ウイルス感染を処置するための組成物および方法 |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP3331571A4 (OSRAM) |
| JP (1) | JP2018516983A (OSRAM) |
| CA (1) | CA3000189A1 (OSRAM) |
| WO (1) | WO2016196273A1 (OSRAM) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6261500B2 (ja) | 2011-07-22 | 2018-01-17 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ヌクレアーゼ切断特異性の評価および改善 |
| US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| US9737604B2 (en) | 2013-09-06 | 2017-08-22 | President And Fellows Of Harvard College | Use of cationic lipids to deliver CAS9 |
| US9228207B2 (en) | 2013-09-06 | 2016-01-05 | President And Fellows Of Harvard College | Switchable gRNAs comprising aptamers |
| US9068179B1 (en) | 2013-12-12 | 2015-06-30 | President And Fellows Of Harvard College | Methods for correcting presenilin point mutations |
| US10077453B2 (en) | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
| WO2016196282A1 (en) * | 2015-05-29 | 2016-12-08 | Agenovir Corporation | Compositions and methods for cell targeted hpv treatment |
| EP3365356B1 (en) | 2015-10-23 | 2023-06-28 | President and Fellows of Harvard College | Nucleobase editors and uses thereof |
| JP7231935B2 (ja) | 2016-08-03 | 2023-03-08 | プレジデント アンド フェローズ オブ ハーバード カレッジ | アデノシン核酸塩基編集因子およびそれらの使用 |
| EP3497214B1 (en) | 2016-08-09 | 2023-06-28 | President and Fellows of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
| WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| EP3526320A1 (en) | 2016-10-14 | 2019-08-21 | President and Fellows of Harvard College | Aav delivery of nucleobase editors |
| US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
| WO2018165631A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Cancer vaccine |
| WO2018165504A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| KR20190127797A (ko) | 2017-03-10 | 2019-11-13 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 시토신에서 구아닌으로의 염기 편집제 |
| KR20240116572A (ko) | 2017-03-23 | 2024-07-29 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제 |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| WO2019023680A1 (en) | 2017-07-28 | 2019-01-31 | President And Fellows Of Harvard College | METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE) |
| EP3676376B1 (en) | 2017-08-30 | 2025-01-15 | President and Fellows of Harvard College | High efficiency base editors comprising gam |
| CN111757937A (zh) | 2017-10-16 | 2020-10-09 | 布罗德研究所股份有限公司 | 腺苷碱基编辑器的用途 |
| WO2019118949A1 (en) | 2017-12-15 | 2019-06-20 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| CN112654710A (zh) | 2018-05-16 | 2021-04-13 | 辛瑟高公司 | 用于指导rna设计和使用的方法和系统 |
| US12157760B2 (en) | 2018-05-23 | 2024-12-03 | The Broad Institute, Inc. | Base editors and uses thereof |
| US12281338B2 (en) | 2018-10-29 | 2025-04-22 | The Broad Institute, Inc. | Nucleobase editors comprising GeoCas9 and uses thereof |
| WO2020154500A1 (en) | 2019-01-23 | 2020-07-30 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| MX2021011426A (es) | 2019-03-19 | 2022-03-11 | Broad Inst Inc | Metodos y composiciones para editar secuencias de nucleótidos. |
| EP3956349A1 (en) | 2019-04-17 | 2022-02-23 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| MX2022014008A (es) | 2020-05-08 | 2023-02-09 | Broad Inst Inc | Métodos y composiciones para la edición simultánea de ambas cadenas de una secuencia de nucleótidos de doble cadena objetivo. |
| JP2023540427A (ja) * | 2020-07-07 | 2023-09-25 | オリエンジーン バイオテクノロジー リミテッド | Ｈｓｖ－１遺伝子編集のためのガイドｒｎａおよびその方法 |
| US20240301372A1 (en) * | 2021-01-25 | 2024-09-12 | Fred Hutchinson Cancer Center | Treatment for hsv-1 using a meganuclease |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150098954A1 (en) * | 2013-10-08 | 2015-04-09 | Elwha Llc | Compositions and Methods Related to CRISPR Targeting |
-
2016
- 2016-05-27 JP JP2018513744A patent/JP2018516983A/ja active Pending
- 2016-05-27 EP EP16804107.7A patent/EP3331571A4/en not_active Withdrawn
- 2016-05-27 WO PCT/US2016/034606 patent/WO2016196273A1/en not_active Ceased
- 2016-05-27 CA CA3000189A patent/CA3000189A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018516983A5 (OSRAM) | ||
| JP2018516984A5 (OSRAM) | ||
| Ho et al. | Next‐generation vaccines: nanoparticle‐mediated DNA and mRNA delivery | |
| US20170246261A1 (en) | Antiviral treatment with low immunogenicity | |
| Kaur et al. | Modified mRNA as a therapeutic tool for the heart | |
| US10117911B2 (en) | Compositions and methods to treat herpes simplex virus infections | |
| Liu et al. | Systemic delivery of CRISPR/Cas9 with PEG-PLGA nanoparticles for chronic myeloid leukemia targeted therapy | |
| Phua et al. | Transfection efficiency and transgene expression kinetics of mRNA delivered in naked and nanoparticle format | |
| US10066241B2 (en) | Compositions and methods of delivering treatments for latent viral infections | |
| JP2017518075A5 (OSRAM) | ||
| US20170087224A1 (en) | Delivery methods and compositions | |
| JP2018516983A (ja) | ウイルス感染を処置するための組成物および方法 | |
| US20200230259A1 (en) | Isolation of extracellular vesicles (evs) from red blood cells for gene therapy | |
| Singh et al. | Transdermal delivery for gene therapy | |
| JP2018532403A5 (OSRAM) | ||
| JP2018516597A (ja) | 移植のために細胞を処置する方法および組成物 | |
| Goodwin et al. | Nonviral vectors: we have come a long way | |
| CN105518149A (zh) | 靶细胞内治疗性蛋白的靶向产生的系统和方法 | |
| JP2020505390A (ja) | Ｃｒｉｓｐｒ治療薬を送達するためのウイルスベクターとしてのレンチウイルスおよび非組み込みレンチウイルス | |
| Mohamad Razif et al. | Emergence of mRNA vaccines in the management of cancer | |
| Yuan et al. | Post cross-linked ROS-responsive poly (β-amino ester)-plasmid polyplex NPs for gene therapy of EBV-associated nasopharyngeal carcinoma | |
| Lindsay-Mosher et al. | Cancer gene therapy: innovations in therapeutic delivery of CRISPR-Cas9 | |
| JP2025520663A (ja) | 交流電場とｃｒｉｓｐｒ－ｃａｓシステムを用いた症状および疾患の治療システムおよび方法 | |
| Singh et al. | The Junction of Biomaterials and Gene Therapy–Current Strategies and Future Directions | |
| Massadeh et al. | Polymer nanoparticles for targeted gene delivery |